4-Benzyloxyaniline

4-Benzyloxyaniline

SCHEMBL5571271

Nc1ccc(F)cc1.Nc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 11/20 0.83
RAB9A P51151 2/20 0.82
GAA P10253 1/20 0.82
MAPT P10636 1/20 0.82
MAOA P21397 1/20 0.82
SMN1; SMN2 Q16637 1/20 0.82
L3MBTL1 Q9Y468 1/20 0.82
NPC1 O15118 1/20 0.61
MEN1 O00255 1/20 0.59
ALDH1A1 P00352 1/20 0.59
RECQL P46063 1/20 0.59
KMT2A Q03164 1/20 0.59
F2 P00734 1/20 0.58
PRSS1 P07477 1/20 0.58
LMNA P02545 1/20 0.56
CYP1A2 P05177 1/20 0.56
PTGS1 P23219 1/20 0.56
SLC6A2 P23975 1/20 0.56
CYP2C19 P33261 1/20 0.56
PTGS2 P35354 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1578152 0.91 MAOB (1.00) MAOBRAB9AGAAMAPTMAOA
4-Benzyloxyaniline SCHEMBL171449 0.91 MAOB (1.00) MAOBRAB9AGAAMAPTMAOA
SCHEMBL4337813 0.91 MEN1 (0.68) MAOBRAB9AGAAMAPTMAOA
4-Benzyloxyaniline SCHEMBL371743 0.89 MAOB (0.96) MAOBRAB9AGAAMAPTMAOA
4-Benzyloxyaniline SCHEMBL5376217 0.89 MAOB (0.96) MAOBRAB9AGAAMAPTMAOA
SCHEMBL5045790 0.85 MAOB (0.89) MAOBRAB9AGAAMAPTMAOA
SCHEMBL6733465 0.85 MAOB (0.89) MAOBRAB9AGAAMAPTMAOA
SCHEMBL11840257 0.84 MAOB (0.62) MAOBRAB9AGAAMAPTMAOA
SCHEMBL6927496 0.83 MAOB (0.66) MAOBMAOAMEN1ALDH1A1RECQL
SCHEMBL323938 0.83 MAOB (0.84) MAOBRAB9AGAAMAPTMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 US disclosed
US-20140155378-A9 c-Met Modulators and Method of Use EXELIXIS, INC. (US) 2014-06-05 US disclosed
US-20130252940-A1 c-Met Modulators and Method of Use EXELIXIS, INC. (US) 2013-09-26 US disclosed
US-8497284-B2 C-met modulators and method of use EXELIXIS, INC. (US) 2013-07-30 US disclosed
US-8476298-B2 c-Met modulators and method of use EXELIXIS, INC. (US) 2013-07-02 US disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155378-A9 c-Met Modulators and Method of Use FLT4, MET, FLT1 MAOB 1596/4885RAB9A 3263/4885GAA 3321/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MAOB 1371/4885RAB9A 3070/4885GAA 3255/4885
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MAOB 1596/4885RAB9A 3263/4885GAA 3321/4885
US-20130252940-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 MAOB 1596/4885RAB9A 3263/4885GAA 3321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.